本文已被:浏览 183次 下载 204次
Received:October 18, 2023 Published Online:June 20, 2024
Received:October 18, 2023 Published Online:June 20, 2024
中文摘要: 有效的检测方法能够在早期发现恶性肿瘤迹象,提高患者生存率。液体活检,作为一项新兴的无创技术,通过检测体液中的生物标志物,为恶性肿瘤提供全方位的信息,从而指导更加精准的治疗。液体活检的主要检测指标包括循环肿瘤DNA、循环肿瘤细胞、微小RNA和外泌体等。通过使用不同的技术手段检测这些生物标志物,可以为不同发展阶段的肿瘤提供治疗方向,延长患者的生存期,提高生活质量。相较于传统组织检测,液体活检作为一种非侵入式的手段,具有无创性,克服肿瘤异质性及可以实时监测肿瘤情况等优势。随着技术的不断发展,液体活检在早期、中期和晚期恶性肿瘤治疗中都具有重要的临床指导价值,包括指导肿瘤治疗、研究抗药性机制、预测患者预后、监测复发以及协助早期筛查和诊断。本文将综述当前液体活检技术的发展状况,深入分析液体活检所使用的生物标志物,探讨其在肿瘤诊疗全程管理中的研究进展。
Abstract:Effective detection methods play a pivotal role in early identification of cancer signal, thereby enhancing patient survival rates. Liquid biopsy, as a burgeoning non-invasive technology, provides comprehensive tumor information through body fluid analysis, thus guiding precise cancer treatment. Key biomarkers in liquid biopsy encompass circulating tumor DNA, circulating tumor cells, micro-RNA, exosomes, etc. Leveraging diverse techniques for distinct biomarker detection offers tailored guidance for tumor treatments across different stages, prolongs patient survival, and improves life quality. In contrast to tissue biopsies, liquid biopsy boasts non-invasiveness, surmounts tumor heterogeneity and enables real-time dynamic monitoring. With continual technological evolution, liquid biopsy has demonstrated pivotal clinical guidance in early, intermediate, and advanced-stage cancers, encompassing treatment guidance, drug resistance mechanism exploration, patient prognosis prediction, recurrence monitoring, and facilitating early tumor screening. This article conducts an in-depth analysis of liquid biopsy technology and biomarkers while summarizing and discussing its research advancements in the comprehensive management of tumor diagnosis and treatment.
keywords: Tumor Liquid biopsy Whole-process management Extracellular vesicles Circulating tumor cells Minor residual disease Methylation Fragment omics Micro-RNA
文章编号: 中图分类号:R73 文献标志码:A
基金项目:南京市卫生科技发展重大项目(ZDX21001)
引用文本: